Pulmonary hypertension (PH) is a devastating disease with high levels of morbidity and mortality and no cure. Despite the disease’s rarity, the potential commercial opportunities for drugs approved for PH are considerable, driven by premium pricing and the propensity for polypharmacy. Although this market has become congested, commercial interest in PH remains high. The need for more-efficacious and disease-modifying agents fuels this attention, along with the unserved populations lacking approved treatments.
Questions answered
- Novel agents such as United Therapeutics’ ralinepag, Merck & Co.’s sotatercept, Liquidia’s Yutrepia, and United Therapeutics / MannKind’s Tyvaso DPI are in late-phase development for PH. What do interviewed thought leaders say about the advantages and disadvantages of these therapies? How will the launch of these agents affect prescribing decisions?
- Generic formulations of several key branded therapies have launched in recent years. How have these launches impacted prescribing patterns? What effect has generic launches had on entrenched and emerging branded therapies?
- The treatment of PH World Health Organization groups 2, 3, and 5 is associated with substantial unmet need. What are the other key unmet needs in PH treatment? How likely are these unmet needs to be fulfilled during the forecast period?
- Patients with pulmonary arterial hypertension are usually prescribed PDE-5 inhibitors and/or ERAs as first-line therapy. What are the treatment guidelines for later lines of therapy? How does treatment vary between countries / geographical regions?
Content highlights
Geographies: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
Key drugs covered: Uptravi, Orenitram, Adempas, Opsumit, Adcirca, Tracleer, Revatio, Letairis / Volibris, Remodulin, Flolan, Veletri, Tyvaso, Ventavis, Beraprost, ralinepag, Yutrepia, Tyvaso DPI, sotatercept, macitentan / tadalafil FDC.
Key companies mentioned: Actelion, United Therapeutics, Bayer HealthCare, GlaxoSmithKline, Gilead Sciences, Pfizer, Mannkind Corporation, Merck & Co., Liquidia Technologies.
Product description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Solution enhancement
Disease Landscape & Forecast features continual updates to provide timely insights and analyses as meaningful indication-specific news and events unfold.
Sayani Datta, M.Sc.
Sayani Datta, M.Sc., is a principal analyst on the Cardiovascular, Metabolic, Renal, and Hematologic (CMRH) Disorders team at Clarivate. Her primary area of focus is nonalcoholic steatohepatitis (NASH). She has worked on various types of custom and syndicated research projects in several therapeutic areas and has experience in sales- and epidemiology-based forecasting, commercial opportunity assessments, and market tracking and intelligence. She holds a master of science degree in biotechnology from the University of Leeds, where she gained exposure to life sciences research and development working as a postgraduate research intern.
Ullas Ulahannan
Ullas Ulahannan, M.P.H., is an associate epidemiologist at Clarivate. Previously, he worked at Jhpiego (a John Hopkins University affiliate) as a senior program officer evaluating, implementing, and monitoring various health programs in collaboration with the state and central governments of India. He earned a B.S. in nursing from Rajiv Gandhi University and an M.P.H. from Manipal University.